Cowen analyst Chris Shibutani reiterated an Outperform rating on Mirati Therapeutics (NASDAQ: MRTX) believing pipeline has shifted over the past ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE